`ASSOCIATE
`
`(202) 772-8787
`MBODENSTEIN@SKGF.COM
`
`June 12, 2015
`
`Commissioner for Patents
`PO Box 1450
`
`Alexandria, VA 223 1 3- 1450
`
`//’tz/
`
`// 7/71",
`
`l/I/I/I/Ifi,////////
`~./"$1
`
`Con ttrmation N0. 1 091
`Art Unit 1628
`
`Re:
`
`US. Track 1 Patent Application
`Appl. No. 14/500,409; Filed: September 29, 2014
`For:
`Buprenorphine—Wafer for Drug Substitution Therapy
`Inventors: OKSCHE et al.
`
`Our Ref: 1861 .2700001/JMC/MSB
`
`Commissioner:
`
`Transmitted herewith for appropriate action is a request for Express Abandonment Under
`37 CPR. § 1.138. This document is being filed electronically through EFS-Web.
`
`The US. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
`or credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`
`Attorney for Applicants
`Registration No. 58,885
`
`MSB :dbj
`Enclosure
`
`201372971
`
`